Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection
Abstract Background Tobramycin inhalation solution (TIS) and chronic azithromycin (AZ) have known clinical benefits for children with CF, likely due to antimicrobial and anti-inflammatory activity. The effects of chronic AZ in combination with TIS on the airway microbiome have not been extensively i...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Microbiology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12866-023-03073-8 |
| _version_ | 1827781252057399296 |
|---|---|
| author | Brandie D. Wagner Edith T. Zemanick Scott D. Sagel Charles E. Robertson Mark J. Stevens Nicole Mayer-Hamblett George Retsch-Bogart Bonnie W. Ramsey J. Kirk Harris |
| author_facet | Brandie D. Wagner Edith T. Zemanick Scott D. Sagel Charles E. Robertson Mark J. Stevens Nicole Mayer-Hamblett George Retsch-Bogart Bonnie W. Ramsey J. Kirk Harris |
| author_sort | Brandie D. Wagner |
| collection | DOAJ |
| description | Abstract Background Tobramycin inhalation solution (TIS) and chronic azithromycin (AZ) have known clinical benefits for children with CF, likely due to antimicrobial and anti-inflammatory activity. The effects of chronic AZ in combination with TIS on the airway microbiome have not been extensively investigated. Oropharyngeal swab samples were collected in the OPTIMIZE multicenter, randomized, placebo-controlled trial examining the addition of AZ to TIS in 198 children with CF and early P. aeruginosa infection. Bacterial small subunit rRNA gene community profiles were determined. The effects of TIS and AZ were assessed on oropharyngeal microbial diversity and composition to uncover whether effects on the bacterial community may be a mechanism of action related to the observed changes in clinical outcomes. Results Substantial changes in bacterial communities (total bacterial load, diversity and relative abundance of specific taxa) were observed by week 3 of TIS treatment for both the AZ and placebo groups. On average, these shifts were due to changes in non-traditional CF taxa that were not sustained at the later study visits (weeks 13 and 26). Bacterial community measures did not differ between the AZ and placebo groups. Conclusions This study provides further evidence that the mechanism for AZ’s effect on clinical outcomes is not due solely to action on airway microbial composition. |
| first_indexed | 2024-03-11T15:16:15Z |
| format | Article |
| id | doaj.art-d5da65057c594b7ab884fe12599e5df7 |
| institution | Directory Open Access Journal |
| issn | 1471-2180 |
| language | English |
| last_indexed | 2024-03-11T15:16:15Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Microbiology |
| spelling | doaj.art-d5da65057c594b7ab884fe12599e5df72023-10-29T12:16:24ZengBMCBMC Microbiology1471-21802023-10-0123111110.1186/s12866-023-03073-8Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infectionBrandie D. Wagner0Edith T. Zemanick1Scott D. Sagel2Charles E. Robertson3Mark J. Stevens4Nicole Mayer-Hamblett5George Retsch-Bogart6Bonnie W. Ramsey7J. Kirk Harris8Department of Biostatistics and Informatics, Colorado School of Public Health, University of ColoradoChildren’s Hospital ColoradoChildren’s Hospital ColoradoDepartment of Infectious Diseases, University of ColoradoChildren’s Hospital ColoradoDepartment of Pediatrics, University of WashingtonDepartment of Pediatrics, University of North CarolinaDepartment of Pediatrics, University of WashingtonChildren’s Hospital ColoradoAbstract Background Tobramycin inhalation solution (TIS) and chronic azithromycin (AZ) have known clinical benefits for children with CF, likely due to antimicrobial and anti-inflammatory activity. The effects of chronic AZ in combination with TIS on the airway microbiome have not been extensively investigated. Oropharyngeal swab samples were collected in the OPTIMIZE multicenter, randomized, placebo-controlled trial examining the addition of AZ to TIS in 198 children with CF and early P. aeruginosa infection. Bacterial small subunit rRNA gene community profiles were determined. The effects of TIS and AZ were assessed on oropharyngeal microbial diversity and composition to uncover whether effects on the bacterial community may be a mechanism of action related to the observed changes in clinical outcomes. Results Substantial changes in bacterial communities (total bacterial load, diversity and relative abundance of specific taxa) were observed by week 3 of TIS treatment for both the AZ and placebo groups. On average, these shifts were due to changes in non-traditional CF taxa that were not sustained at the later study visits (weeks 13 and 26). Bacterial community measures did not differ between the AZ and placebo groups. Conclusions This study provides further evidence that the mechanism for AZ’s effect on clinical outcomes is not due solely to action on airway microbial composition.https://doi.org/10.1186/s12866-023-03073-8MicrobiomeOropharyngeal swabMacrolidesPulmonary exacerbationTobramycinBeta diversity |
| spellingShingle | Brandie D. Wagner Edith T. Zemanick Scott D. Sagel Charles E. Robertson Mark J. Stevens Nicole Mayer-Hamblett George Retsch-Bogart Bonnie W. Ramsey J. Kirk Harris Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection BMC Microbiology Microbiome Oropharyngeal swab Macrolides Pulmonary exacerbation Tobramycin Beta diversity |
| title | Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection |
| title_full | Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection |
| title_fullStr | Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection |
| title_full_unstemmed | Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection |
| title_short | Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection |
| title_sort | limited effects of azithromycin on the oropharyngeal microbiome in children with cf and early pseudomonas infection |
| topic | Microbiome Oropharyngeal swab Macrolides Pulmonary exacerbation Tobramycin Beta diversity |
| url | https://doi.org/10.1186/s12866-023-03073-8 |
| work_keys_str_mv | AT brandiedwagner limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT edithtzemanick limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT scottdsagel limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT charleserobertson limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT markjstevens limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT nicolemayerhamblett limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT georgeretschbogart limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT bonniewramsey limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection AT jkirkharris limitedeffectsofazithromycinontheoropharyngealmicrobiomeinchildrenwithcfandearlypseudomonasinfection |